Report Code: CMI45047

Published Date: April 2024

Pages: 320+

Category: Healthcare

Report Snapshot

CAGR: 11.5%
158.2M
2023
176.4M
2024
469.8M
2033

Source: CMI

Study Period: 2024-2033
Fastest Growing Market: Asia-Pacific
Largest Market: Europe

Major Players

  • Elekta AB
  • Cerner Corporation
  • McKesson Corporation
  • IBM Watson Health
  • iSalus Healthcare
  • Others

Exclusive, in-depth market intelligence can help you increase your Revenue.

Download Sample Pdf

Reports Description

As per the current market research conducted by the CMI Team, the global Cancer Registry Software Market is expected to record a CAGR of 11.5% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 176.4 Million. By 2033, the valuation is anticipated to reach USD 469.8 Million.

The Cancer Registry Software Market encompasses the segment of healthcare technology dedicated to managing and analyzing data related to cancer cases. This software facilitates the collection, storage, analysis, and reporting of cancer-related information, including patient demographics, tumor characteristics, treatment modalities, and outcomes.

It plays a crucial role in cancer surveillance, epidemiological research, quality improvement initiatives, and regulatory compliance. Cancer registry software solutions are utilized by hospitals, cancer centers, research institutions, and public health agencies to track cancer trends, evaluate treatment effectiveness, and inform public health policies and interventions aimed at reducing the burden of cancer.

Cancer Registry Software Market – Significant Growth Factors

The Cancer Registry Software Market presents significant growth opportunities due to several factors:

  • Increasing Cancer Incidence: The rising incidence of cancer globally is a primary driver of the Cancer Registry Software Market. As the number of cancer cases continues to grow, there is a greater need for efficient data management and analysis tools to track and monitor cancer trends, treatment outcomes, and survival rates.
  • Regulatory Compliance Requirements: Stringent regulatory requirements for cancer reporting and data management drive the adoption of Cancer Registry Software solutions. Healthcare facilities, including hospitals and cancer centers, need to comply with regulations and accreditation standards, such as those set forth by the American College of Surgeons Commission on Cancer (CoC), which mandate the use of certified cancer registry software.
  • Advancements in Technology: Technological advancements, such as cloud computing, artificial intelligence, and big data analytics, are transforming the Cancer Registry Software Market. These innovations enable more efficient data collection, storage, analysis, and reporting, leading to improved accuracy, completeness, and accessibility of cancer registry data.
  • Focus on Population Health Management: There is a growing emphasis on population health management strategies to address cancer prevention, early detection, and treatment outcomes. Cancer registry software plays a vital role in population health initiatives by providing comprehensive data analytics capabilities to identify trends, disparities, and opportunities for intervention in cancer care delivery.
  • Expansion of Telemedicine and Remote Monitoring: The increasing adoption of telemedicine and remote monitoring technologies presents an opportunity for Cancer Registry Software vendors to develop solutions that support virtual cancer care delivery models. Integrating telemedicine platforms with cancer registry software can facilitate remote data collection, follow-up care, and patient monitoring, enhancing the efficiency and accessibility of cancer registry data.

Cancer Registry Software Market – Mergers and Acquisitions

The Cancer Registry Software Market has seen several mergers and acquisitions in recent years, with companies seeking to expand their market presence and leverage synergies to improve their product offerings and profitability. Some notable examples of mergers and acquisitions in the Cancer Registry Software Market include:

  • In 2022, Kaiku Health and Roche have formed a strategic partnership in digital patient monitoring and management (DPMM), aiming to deploy digital tools for real-time symptom management, enhancing patient support, and delivering personalized cancer care to clinics and patients worldwide.
  • In 2022, Venus Remedies Limited unveils the launch of its consumer healthcare division, offering a range of products dedicated to pain management, further diversifying its portfolio and expanding its presence in the consumer health market segment.
  • In 2022, Gamida Cell’s allogeneic cell therapy Omisirge received FDA approval, promising to enhance access to stem cell transplants and improve patient outcomes. This milestone marks a significant advancement in the field of cell therapy and offers hope for patients in need of transplantation.

These mergers and acquisitions have helped companies expand their product offerings, improve their market presence, and capitalize on growth opportunities in the Cancer Registry Software Market. The trend is expected to continue as companies seek to gain a competitive edge in the market.

COMPARATIVE ANALYSIS OF THE RELATED MARKET

Cancer Registry Software Market Liver Cancer Market Hereditary Cancer Testing Market
CAGR 11.5% (Approx) CAGR 14.5% (Approx) CAGR 7.5% (Approx)
USD 469.8 Million by 2033 USD 16.3 Billion by 2033 USD 12.1 Billion by 2033

Cancer Registry Software Market – Significant Threats

The Cancer Registry Software Market faces several significant threats that could impact its growth and profitability in the future. Some of these threats include:

  • Data Security and Privacy Concerns: The increasing volume of sensitive patient data stored and managed by cancer registry software systems raises concerns about data security and privacy breaches. Unauthorized access, data breaches, and cyberattacks pose significant threats to patient confidentiality, organizational reputation, and regulatory compliance.
  • Limited Interoperability: Incompatibility and lack of interoperability between different cancer registry software systems hinder data sharing and collaboration among healthcare organizations. This fragmentation in data exchange poses challenges in aggregating and analyzing comprehensive cancer registry data, limiting the effectiveness of cancer surveillance and research efforts.
  • Resource Constraints: Healthcare organizations face resource constraints, including limited funding, staffing shortages, and competing priorities, which may impact their ability to implement and maintain cancer registry software systems effectively. Insufficient resources for training, technical support, and system upgrades can compromise data quality, accuracy, and timeliness, undermining the value of cancer registry data for decision-making and public health initiatives.
  • Regulatory Compliance Burdens: Stringent regulatory requirements and accreditation standards for cancer reporting impose significant administrative burdens on healthcare facilities. Compliance with regulations such as those set forth by the American College of Surgeons Commission on Cancer (CoC) requires ongoing investment in staff training, system upgrades, and quality assurance measures, increasing the cost and complexity of cancer registry operations.

Global Cancer Registry Software Market 2024–2033 (By Deployment Mode)

www.custommarketinsight.com

Category-Wise Insights

By Functionality

  • Patient Management: Patient management functionality in Cancer Registry Software involves capturing and organizing patient demographics, diagnosis, treatment details, and follow-up care. Trends include the integration of patient portals for self-management, telemedicine features for remote consultations, and personalized care plans tailored to individual patient needs.
  • Treatment Planning: Treatment planning functionality assists healthcare providers in creating and managing comprehensive treatment plans for cancer patients. Trends include the integration of decision support tools, evidence-based treatment protocols, and multidisciplinary care coordination features to optimize treatment outcomes and minimize treatment-related complications.
  • Outcome Reporting: Outcome reporting functionality enables the tracking, analysis, and reporting of cancer treatment outcomes, survival rates, and quality metrics. Trends include the use of real-time analytics, benchmarking tools, and population health management features to monitor patient outcomes, identify trends, and drive continuous quality improvement initiatives.
  • Follow-up and Survivorship Care: Follow-up and survivorship care functionality supports long-term monitoring and management of cancer survivors post-treatment. Trends include survivorship care planning tools, survivorship clinics, and survivorship care coordination services to address ongoing healthcare needs, monitor for late effects of treatment, and promote wellness and quality of life.
  • Quality Improvement: Quality improvement functionality facilitates the identification, analysis, and improvement of cancer care quality and outcomes. Trends include the implementation of performance dashboards, quality metrics tracking tools, and accreditation support features to enhance adherence to clinical guidelines, optimize resource utilization, and drive continuous quality improvement efforts.

By Type of Cancer

  • Breast Cancer: Breast cancer registry software manages data related to breast cancer cases, including patient demographics, tumor characteristics, and treatment outcomes. Trends include enhanced survivorship tracking, risk assessment tools, and integration with mammography systems for early detection.
  • Lung Cancer: Lung cancer registry software tracks data on lung cancer cases, facilitating analysis of patient demographics, disease staging, and treatment modalities. Trends include advancements in imaging integration, predictive analytics for prognosis, and targeted therapies based on molecular profiling.
  • Prostate Cancer: Prostate cancer registry software records data on prostate cancer patients, enabling analysis of screening practices, treatment patterns, and long-term outcomes. Trends include the implementation of active surveillance protocols, integration with prostate-specific antigen (PSA) testing systems, and support for genomic profiling.
  • Colorectal Cancer: Colorectal cancer registry software manages data on colorectal cancer cases, including tumor characteristics, treatment regimens, and surveillance protocols. Trends include risk stratification algorithms, implementation of colorectal cancer screening programs, and integration with pathology systems for histological data analysis.
  • Others: For other types of cancer, registry software captures data on various cancer types, allowing analysis of epidemiological trends, treatment patterns, and survival rates. Trends include interoperability initiatives for data sharing, real-time analytics for population health management, and patient engagement tools for personalized care.

Global Cancer Registry Software Market 2024–2033 (By Type of Cancer)

www.custommarketinsight.com

By Deployment Mode

  • On-premises: On-premises deployment involves hosting Cancer Registry Software within an organization’s local infrastructure, providing direct control over data management and security. Trends include a gradual shift towards cloud-based solutions but a continued preference for on-premises deployments among organizations with strict data security and compliance requirements.
  • Cloud-based: Cloud-based deployment of Cancer Registry Software involves hosting the software on remote servers accessed via the internet. Trends include increased adoption due to scalability, cost-effectiveness, and flexibility. Cloud-based solutions offer improved accessibility, collaboration, and integration capabilities, supporting data-driven decision-making and population health initiatives in the Cancer Registry Software Market.

By End User

  • Hospitals: Hospitals utilize Cancer Registry Software to track and analyze cancer patient data, treatment outcomes, and trends. Trends include the integration of registry software with electronic health records (EHRs), enhancing data accuracy and interoperability, and the adoption of cloud-based solutions for improved accessibility and scalability.
  • Oncology Centers: Oncology Centers rely on Cancer Registry Software to manage cancer patient information, facilitate quality reporting, and support research initiatives. Trends include the customization of software for specialized oncology workflows, the implementation of predictive analytics for personalized treatment planning, and the incorporation of patient-reported outcomes for comprehensive data collection.
  • Government Organizations: Government Organizations use Cancer Registry Software for population-based cancer surveillance, epidemiological research, and public health planning. Trends include the standardization of data reporting requirements, collaboration with healthcare stakeholders to improve data quality, and the utilization of advanced analytics for identifying cancer trends and disparities within communities.
  • Research Institutes: Research Institutes leverage Cancer Registry Software to conduct epidemiological studies, clinical trials, and translational research in oncology. Trends include the integration of registry data with genomic and molecular profiling data for precision medicine research, the development of data-sharing platforms to facilitate collaborative research efforts and the implementation of artificial intelligence for data analysis and hypothesis generation.
  • Others: Other stakeholders, such as cancer advocacy organizations, pharmaceutical companies, and healthcare consulting firms, may also utilize Cancer Registry Software for various purposes. Trends include the customization of software for specific use cases, such as patient advocacy and market research, and the development of mobile applications for patient engagement and data collection in community settings.

Report Scope

Feature of the Report Details
Market Size in 2024 USD 176.4 Million
Projected Market Size in 2033 USD 469.8 Million
Market Size in 2023 USD 158.2 Million
CAGR Growth Rate 11.5% CAGR
Base Year 2023
Forecast Period 2024-2033
Key Segment By Functionality, Type of Cancer, Deployment Mode, End User and Region
Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends
Regional Scope North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America
Buying Options Request tailored purchasing options to fulfil your requirements for research.

Cancer Registry Software Market – Regional Analysis

The Cancer Registry Software Market is segmented into various regions, including North America, Europe, Asia-Pacific, and LAMEA. Here is a brief overview of each region:

  • North America: In North America, a significant trend in the Cancer Registry Software Market is the increasing adoption of cloud-based solutions for cancer data management. Additionally, there is a growing focus on interoperability and data sharing initiatives to facilitate collaboration among healthcare organizations and improve cancer surveillance efforts.
  • Europe: In Europe, a key trend in the Cancer Registry Software Market is the implementation of standardized data reporting requirements and quality assurance measures. Furthermore, there is a rising emphasis on population-based cancer registries and epidemiological research to inform public health policies and cancer prevention strategies.
  • Asia-Pacific: In the Asia-Pacific region, a notable trend in the Cancer Registry Software Market is the expansion of cancer registry infrastructure and capacity-building efforts. This includes the development of national cancer registries, training programs for registry staff, and the adoption of innovative technologies to enhance data collection and analysis capabilities.
  • LAMEA (Latin America, Middle East, and Africa): In the LAMEA region, a key trend in the Cancer Registry Software Market is the increasing investment in cancer control programs and healthcare infrastructure. There is a growing recognition of the importance of cancer surveillance and registry systems in addressing the burden of cancer and improving patient outcomes across diverse healthcare settings.

Global Cancer Registry Software Market 2024–2033 (By Million)

www.custommarketinsight.com

Competitive Landscape – Cancer Registry Software Market

The Cancer Registry Software Market is highly competitive, with a large number of manufacturers and retailers operating globally. Some of the key players in the market include:

  • Elekta AB
  • Cerner Corporation
  • McKesson Corporation
  • IBM Watson Health
  • iSalus Healthcare
  • Onco, Inc.
  • MRS Systems Inc.
  • Ordinal Data Inc.
  • Rocky Mountain Cancer Data Systems Inc.
  • Elekta AB
  • Conduent Inc.
  • Epic Systems Corporation
  • Medstreaming LLC
  • Flatiron Health Inc.
  • Varian Medical Systems Inc.
  • Others

These companies operate in the market through various strategies such as product innovation, mergers and acquisitions, and partnerships.

New players entering the Cancer Registry Software Market often adopt innovative approaches to differentiate themselves. Startups and emerging companies leverage advancements in artificial intelligence, cloud computing, and interoperability to develop user-friendly and feature-rich solutions.

Meanwhile, established key players such as Elekta AB, Cerner Corporation, and McKesson Corporation dominate the market due to their extensive experience, robust product offerings, and strong market presence.

These key players often lead in market share by continuously innovating, providing comprehensive software suites, and forging strategic partnerships with healthcare organizations to deliver tailored solutions addressing specific needs in cancer registry management.

The Cancer Registry Software Market is segmented as follows:

By Functionality

  • Patient Management
  • Treatment Planning
  • Outcome Reporting
  • Follow-up and Survivorship Care
  • Quality Improvement

By Type of Cancer

  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Others

By Deployment Mode

  • On-premises
  • Cloud-based

By End User

  • Hospitals
  • Oncology Centers
  • Government Organizations
  • Research Institutes
  • Others

Regional Coverage:

North America

  • U.S.
  • Canada
  • Mexico
  • Rest of North America

Europe

  • Germany
  • France
  • U.K.
  • Russia
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • New Zealand
  • Australia
  • South Korea
  • Taiwan
  • Rest of Asia Pacific

The Middle East & Africa

  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa

Latin America

  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

  • Chapter 1. Preface
    • 1.1 Report Description and Scope
    • 1.2 Research scope
    • 1.3 Research methodology
      • 1.3.1 Market Research Type
      • 1.3.2 Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1 Global Cancer Registry Software Market, (2024 – 2033) (USD Billion)
    • 2.2 Global Cancer Registry Software Market: snapshot
  • Chapter 3. Global Cancer Registry Software Market – Industry Analysis
    • 3.1 Cancer Registry Software Market: Market Dynamics
    • 3.2 Market Drivers
      • 3.2.1 Increasing Cancer Incidence
      • 3.2.2 Regulatory Compliance Requirements
      • 3.2.3 Advancements in Technology
      • 3.2.4 Focus on Population Health Management
      • 3.2.5 Expansion of Telemedicine and Remote Monitoring.
    • 3.3 Market Restraints
    • 3.4 Market Opportunities
    • 3.5 Market Challenges
    • 3.6 Porter’s Five Forces Analysis
    • 3.7 Market Attractiveness Analysis
      • 3.7.1 Market Attractiveness Analysis By Functionality
      • 3.7.2 Market Attractiveness Analysis By Type of Cancer
      • 3.7.3 Market Attractiveness Analysis By Deployment Mode
      • 3.7.4 Market Attractiveness Analysis By End User
  • Chapter 4. Global Cancer Registry Software Market- Competitive Landscape
    • 4.1 Company market share analysis
      • 4.1.1 Global Cancer Registry Software Market: Company Market Share, 2023
    • 4.2 Strategic development
      • 4.2.1 Acquisitions & mergers
      • 4.2.2 New Product launches
      • 4.2.3 Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4 Research and development and Regional expansion
    • 4.3 Price trend analysis
  • Chapter 5. Global Cancer Registry Software Market – Functionality Analysis
    • 5.1 Global Cancer Registry Software Market Overview: By Functionality
      • 5.1.1 Global Cancer Registry Software Market Share, By Functionality, 2023 and 2033
    • 5.2 Patient Management
      • 5.2.1 Global Cancer Registry Software Market by Patient Management, 2024 – 2033 (USD Billion)
    • 5.3 Treatment Planning
      • 5.3.1 Global Cancer Registry Software Market by Treatment Planning, 2024 – 2033 (USD Billion)
    • 5.4 Outcome Reporting
      • 5.4.1 Global Cancer Registry Software Market by Outcome Reporting, 2024 – 2033 (USD Billion)
    • 5.5 Follow-up and Survivorship Care
      • 5.5.1 Global Cancer Registry Software Market by Follow-up and Survivorship Care, 2024 – 2033 (USD Billion)
    • 5.6 Quality Improvement
      • 5.6.1 Global Cancer Registry Software Market by Quality Improvement, 2024 – 2033 (USD Billion)
  • Chapter 6. Global Cancer Registry Software Market – Type of Cancer Analysis
    • 6.1 Global Cancer Registry Software Market Overview: By Type of Cancer
      • 6.1.1 Global Cancer Registry Software Market Share, By Type of Cancer, 2023 and 2033
    • 6.2 Breast Cancer
      • 6.2.1 Global Cancer Registry Software Market by Breast Cancer, 2024 – 2033 (USD Billion)
    • 6.3 Lung Cancer
      • 6.3.1 Global Cancer Registry Software Market by Lung Cancer, 2024 – 2033 (USD Billion)
    • 6.4 Prostate Cancer
      • 6.4.1 Global Cancer Registry Software Market by Prostate Cancer, 2024 – 2033 (USD Billion)
    • 6.5 Colorectal Cancer
      • 6.5.1 Global Cancer Registry Software Market by Colorectal Cancer, 2024 – 2033 (USD Billion)
    • 6.6 Others
      • 6.6.1 Global Cancer Registry Software Market by Others, 2024 – 2033 (USD Billion)
  • Chapter 7. Global Cancer Registry Software Market – Deployment Mode Analysis
    • 7.1 Global Cancer Registry Software Market Overview: By Deployment Mode
      • 7.1.1 Global Cancer Registry Software Market Share, By Deployment Mode, 2023 and 2033
    • 7.2 On-premises
      • 7.2.1 Global Cancer Registry Software Market by On-premises, 2024 – 2033 (USD Billion)
    • 7.3 Cloud-based
      • 7.3.1 Global Cancer Registry Software Market by Cloud-based, 2024 – 2033 (USD Billion)
  • Chapter 8. Global Cancer Registry Software Market – End User Analysis
    • 8.1 Global Cancer Registry Software Market Overview: By End User
      • 8.1.1 Global Cancer Registry Software Market Share, By End User, 2023 and 2033
    • 8.2 Hospitals
      • 8.2.1 Global Cancer Registry Software Market by Hospitals, 2024 – 2033 (USD Billion)
    • 8.3 Oncology Centers
      • 8.3.1 Global Cancer Registry Software Market by Oncology Centers, 2024 – 2033 (USD Billion)
    • 8.4 Government Organizations
      • 8.4.1 Global Cancer Registry Software Market by Government Organizations, 2024 – 2033 (USD Billion)
    • 8.5 Research Institutes
      • 8.5.1 Global Cancer Registry Software Market by Research Institutes, 2024 – 2033 (USD Billion)
    • 8.6 Others
      • 8.6.1 Global Cancer Registry Software Market by Others, 2024 – 2033 (USD Billion)
  • Chapter 9. Cancer Registry Software Market – Regional Analysis
    • 9.1 Global Cancer Registry Software Market Regional Overview
    • 9.2 Global Cancer Registry Software Market Share, by Region, 2023 & 2033 (USD Billion)
    • 9.3. North America
      • 9.3.1 North America Cancer Registry Software Market, 2024 – 2033 (USD Billion)
        • 9.3.1.1 North America Cancer Registry Software Market, by Country, 2024 – 2033 (USD Billion)
    • 9.4 North America Cancer Registry Software Market, by Functionality, 2024 – 2033
      • 9.4.1 North America Cancer Registry Software Market, by Functionality, 2024 – 2033 (USD Billion)
    • 9.5 North America Cancer Registry Software Market, by Type of Cancer, 2024 – 2033
      • 9.5.1 North America Cancer Registry Software Market, by Type of Cancer, 2024 – 2033 (USD Billion)
    • 9.6 North America Cancer Registry Software Market, by Deployment Mode, 2024 – 2033
      • 9.6.1 North America Cancer Registry Software Market, by Deployment Mode, 2024 – 2033 (USD Billion)
    • 9.7 North America Cancer Registry Software Market, by End User, 2024 – 2033
      • 9.7.1 North America Cancer Registry Software Market, by End User, 2024 – 2033 (USD Billion)
    • 9.8. Europe
      • 9.8.1 Europe Cancer Registry Software Market, 2024 – 2033 (USD Billion)
        • 9.8.1.1 Europe Cancer Registry Software Market, by Country, 2024 – 2033 (USD Billion)
    • 9.9 Europe Cancer Registry Software Market, by Functionality, 2024 – 2033
      • 9.9.1 Europe Cancer Registry Software Market, by Functionality, 2024 – 2033 (USD Billion)
    • 9.10 Europe Cancer Registry Software Market, by Type of Cancer, 2024 – 2033
      • 9.10.1 Europe Cancer Registry Software Market, by Type of Cancer, 2024 – 2033 (USD Billion)
    • 9.11 Europe Cancer Registry Software Market, by Deployment Mode, 2024 – 2033
      • 9.11.1 Europe Cancer Registry Software Market, by Deployment Mode, 2024 – 2033 (USD Billion)
    • 9.12 Europe Cancer Registry Software Market, by End User, 2024 – 2033
      • 9.12.1 Europe Cancer Registry Software Market, by End User, 2024 – 2033 (USD Billion)
    • 9.13. Asia Pacific
      • 9.13.1 Asia Pacific Cancer Registry Software Market, 2024 – 2033 (USD Billion)
        • 9.13.1.1 Asia Pacific Cancer Registry Software Market, by Country, 2024 – 2033 (USD Billion)
    • 9.14 Asia Pacific Cancer Registry Software Market, by Functionality, 2024 – 2033
      • 9.14.1 Asia Pacific Cancer Registry Software Market, by Functionality, 2024 – 2033 (USD Billion)
    • 9.15 Asia Pacific Cancer Registry Software Market, by Type of Cancer, 2024 – 2033
      • 9.15.1 Asia Pacific Cancer Registry Software Market, by Type of Cancer, 2024 – 2033 (USD Billion)
    • 9.16 Asia Pacific Cancer Registry Software Market, by Deployment Mode, 2024 – 2033
      • 9.16.1 Asia Pacific Cancer Registry Software Market, by Deployment Mode, 2024 – 2033 (USD Billion)
    • 9.17 Asia Pacific Cancer Registry Software Market, by End User, 2024 – 2033
      • 9.17.1 Asia Pacific Cancer Registry Software Market, by End User, 2024 – 2033 (USD Billion)
    • 9.18. Latin America
      • 9.18.1 Latin America Cancer Registry Software Market, 2024 – 2033 (USD Billion)
        • 9.18.1.1 Latin America Cancer Registry Software Market, by Country, 2024 – 2033 (USD Billion)
    • 9.19 Latin America Cancer Registry Software Market, by Functionality, 2024 – 2033
      • 9.19.1 Latin America Cancer Registry Software Market, by Functionality, 2024 – 2033 (USD Billion)
    • 9.20 Latin America Cancer Registry Software Market, by Type of Cancer, 2024 – 2033
      • 9.20.1 Latin America Cancer Registry Software Market, by Type of Cancer, 2024 – 2033 (USD Billion)
    • 9.21 Latin America Cancer Registry Software Market, by Deployment Mode, 2024 – 2033
      • 9.21.1 Latin America Cancer Registry Software Market, by Deployment Mode, 2024 – 2033 (USD Billion)
    • 9.22 Latin America Cancer Registry Software Market, by End User, 2024 – 2033
      • 9.22.1 Latin America Cancer Registry Software Market, by End User, 2024 – 2033 (USD Billion)
    • 9.23. The Middle-East and Africa
      • 9.23.1 The Middle-East and Africa Cancer Registry Software Market, 2024 – 2033 (USD Billion)
        • 9.23.1.1 The Middle-East and Africa Cancer Registry Software Market, by Country, 2024 – 2033 (USD Billion)
    • 9.24 The Middle-East and Africa Cancer Registry Software Market, by Functionality, 2024 – 2033
      • 9.24.1 The Middle-East and Africa Cancer Registry Software Market, by Functionality, 2024 – 2033 (USD Billion)
    • 9.25 The Middle-East and Africa Cancer Registry Software Market, by Type of Cancer, 2024 – 2033
      • 9.25.1 The Middle-East and Africa Cancer Registry Software Market, by Type of Cancer, 2024 – 2033 (USD Billion)
    • 9.26 The Middle-East and Africa Cancer Registry Software Market, by Deployment Mode, 2024 – 2033
      • 9.26.1 The Middle-East and Africa Cancer Registry Software Market, by Deployment Mode, 2024 – 2033 (USD Billion)
    • 9.27 The Middle-East and Africa Cancer Registry Software Market, by End User, 2024 – 2033
      • 9.27.1 The Middle-East and Africa Cancer Registry Software Market, by End User, 2024 – 2033 (USD Billion)
  • Chapter 10. Company Profiles
    • 10.1 Elekta AB
      • 10.1.1 Overview
      • 10.1.2 Financials
      • 10.1.3 Product Portfolio
      • 10.1.4 Business Strategy
      • 10.1.5 Recent Developments
    • 10.2 Cerner Corporation
      • 10.2.1 Overview
      • 10.2.2 Financials
      • 10.2.3 Product Portfolio
      • 10.2.4 Business Strategy
      • 10.2.5 Recent Developments
    • 10.3 McKesson Corporation
      • 10.3.1 Overview
      • 10.3.2 Financials
      • 10.3.3 Product Portfolio
      • 10.3.4 Business Strategy
      • 10.3.5 Recent Developments
    • 10.4 IBM Watson Health
      • 10.4.1 Overview
      • 10.4.2 Financials
      • 10.4.3 Product Portfolio
      • 10.4.4 Business Strategy
      • 10.4.5 Recent Developments
    • 10.5 iSalus Healthcare
      • 10.5.1 Overview
      • 10.5.2 Financials
      • 10.5.3 Product Portfolio
      • 10.5.4 Business Strategy
      • 10.5.5 Recent Developments
    • 10.6 Onco Inc.
      • 10.6.1 Overview
      • 10.6.2 Financials
      • 10.6.3 Product Portfolio
      • 10.6.4 Business Strategy
      • 10.6.5 Recent Developments
    • 10.7 MRS Systems Inc.
      • 10.7.1 Overview
      • 10.7.2 Financials
      • 10.7.3 Product Portfolio
      • 10.7.4 Business Strategy
      • 10.7.5 Recent Developments
    • 10.8 Ordinal Data Inc.
      • 10.8.1 Overview
      • 10.8.2 Financials
      • 10.8.3 Product Portfolio
      • 10.8.4 Business Strategy
      • 10.8.5 Recent Developments
    • 10.9 Rocky Mountain Cancer Data Systems Inc.
      • 10.9.1 Overview
      • 10.9.2 Financials
      • 10.9.3 Product Portfolio
      • 10.9.4 Business Strategy
      • 10.9.5 Recent Developments
    • 10.10 Elekta AB
      • 10.10.1 Overview
      • 10.10.2 Financials
      • 10.10.3 Product Portfolio
      • 10.10.4 Business Strategy
      • 10.10.5 Recent Developments
    • 10.11 Conduent Inc.
      • 10.11.1 Overview
      • 10.11.2 Financials
      • 10.11.3 Product Portfolio
      • 10.11.4 Business Strategy
      • 10.11.5 Recent Developments
    • 10.12 Epic Systems Corporation
      • 10.12.1 Overview
      • 10.12.2 Financials
      • 10.12.3 Product Portfolio
      • 10.12.4 Business Strategy
      • 10.12.5 Recent Developments
    • 10.13 Medstreaming LLC
      • 10.13.1 Overview
      • 10.13.2 Financials
      • 10.13.3 Product Portfolio
      • 10.13.4 Business Strategy
      • 10.13.5 Recent Developments
    • 10.14 Flatiron Health Inc.
      • 10.14.1 Overview
      • 10.14.2 Financials
      • 10.14.3 Product Portfolio
      • 10.14.4 Business Strategy
      • 10.14.5 Recent Developments
    • 10.15 Varian Medical Systems Inc.
      • 10.15.1 Overview
      • 10.15.2 Financials
      • 10.15.3 Product Portfolio
      • 10.15.4 Business Strategy
      • 10.15.5 Recent Developments
    • 10.16 Others.
      • 10.16.1 Overview
      • 10.16.2 Financials
      • 10.16.3 Product Portfolio
      • 10.16.4 Business Strategy
      • 10.16.5 Recent Developments
List Of Figures

Figures No 1 to 35

List Of Tables

Tables No 1 to 102

Report Methodology

In order to get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:

Preliminary Data Mining

On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also a number of reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.

Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.

Statistical Model

Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.

Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.

Some of the variables taken into account for forecasting are as follows:

• Industry drivers and constraints, as well as their current and projected impact

• The raw material case, as well as supply-versus-price trends

• Current volume and projected volume growth through 2032

We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.

Primary Validation

This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.

Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.

All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:

• Market leaders

• Suppliers of raw materials

• Suppliers of raw materials

• Buyers.

The following are the primary research objectives:

• To ensure the accuracy and acceptability of our data.

• Gaining an understanding of the current market and future projections.

Data Collection Matrix

Perspective Primary research Secondary research
Supply-side
  • Manufacturers
  • Technology distributors and wholesalers
  • Company reports and publications
  • Government publications
  • Independent investigations
  • Economic and demographic data
Demand-side
  • End-user surveys
  • Consumer surveys
  • Mystery shopping
  • Case studies
  • Reference customers


Market Analysis Matrix

Qualitative analysis Quantitative analysis
  • Industry landscape and trends
  • Market dynamics and key issues
  • Technology landscape
  • Market opportunities
  • Porter’s analysis and PESTEL analysis
  • Competitive landscape and component benchmarking
  • Policy and regulatory scenario
  • Market revenue estimates and forecast up to 2032
  • Market revenue estimates and forecasts up to 2032, by technology
  • Market revenue estimates and forecasts up to 2032, by application
  • Market revenue estimates and forecasts up to 2032, by type
  • Market revenue estimates and forecasts up to 2032, by component
  • Regional market revenue forecasts, by technology
  • Regional market revenue forecasts, by application
  • Regional market revenue forecasts, by type
  • Regional market revenue forecasts, by component

Prominent Player

  • Elekta AB
  • Cerner Corporation
  • McKesson Corporation
  • IBM Watson Health
  • iSalus Healthcare
  • Onco, Inc.
  • MRS Systems Inc.
  • Ordinal Data Inc.
  • Rocky Mountain Cancer Data Systems Inc.
  • Elekta AB
  • Conduent Inc.
  • Epic Systems Corporation
  • Medstreaming LLC
  • Flatiron Health Inc.
  • Varian Medical Systems Inc.
  • Others

FAQs

The key factors driving the Market are Increasing Cancer Incidence, Regulatory Compliance Requirements, Advancements in Technology, Focus on Population Health Management, Expansion of Telemedicine and Remote Monitoring.

The “Patient Management” category dominated the market in 2023.

The key players in the market are Elekta AB, Cerner Corporation, McKesson Corporation, IBM Watson Health, iSalus Healthcare, Onco, Inc., MRS Systems Inc., Ordinal Data Inc., Rocky Mountain Cancer Data Systems Inc., Elekta AB, Conduent Inc., Epic Systems Corporation, Medstreaming LLC, Flatiron Health Inc., Varian Medical Systems Inc., Others.

“North America” had the largest share in the Cancer Registry Software Market.

The global market is projected to grow at a CAGR of 11.5% during the forecast period, 2024-2033.

The Cancer Registry Software Market size was valued at USD 176.4 Million in 2024.

PURCHASE OPTIONS

$

3490


$

4490


$

5490


$

1950


powerbi pdf
$

6200

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • Free 25% or 40 hours of customisation.
  • Free post-sale service assistance.
  • 15% discount on your next purchase.
  • Dedicated account Associate .
  • Permission to print the report.
  • Service guarantee available.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • Free 35% or 60 hours of customisation.
  • Free post-sale service assistance.
  • 25% discount on your next purchase.
  • Service guarantee available.
  • Personalised market brief by author.
  • Permission to print the report.
  • PDF, Excel and Power Point.
  • Can be accessible by unlimited users.
  • Free 40% or 80 hours of customisation.
  • Free post-sale service assistance.
  • 30% discount on your next purchase.
  • Permission to print the report.
  • Dedicated account manager.
  • Service guarantee available.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
  • 15% discount on your next purchase.
  • Free 20% or 10 hours of customisation.
  • PDF, Excel, Power Point and Power BI.
  • Every Year Free Update ( Apr – Apr)
  • Personalized market brief by author
  • Can be accessible by unlimited users.
  • Free 50% or 90 hours of customization.
  • Up to 50 Company Profiles
  • Free post-sale service assistance with guarantee
  • 40% discount on your next purchase.
  • Permission to print the report.
  • Dedicated account team.
  • Service guarantee available.

Want to customize this report?
100% FREE CUSTOMIZATION!